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The Golden Helix 
Pharmacogenomics Days
The Golden Helix Pharmacogenomics 
Days are international educational scien­
tific meetings that are organized by the 
Golden Helix Institute of Biomedical 
Research jointly with local academic insti­
tutions in major cities with large academic 
hospitals [1,101]. The aim of these meetings 
is: to provide timely updates on the field 
of pharmacogenomics and personalized 
medicine to the local biomedical scien­
tists, healthcare providers and biomedical 
students; to educate and inform them on 
the application of pharmacogenomics in 
modern medical practice; and to bring 
together faculty members from universi­
ties and research institutes from the local 
scientific arena working in the field of 
pharmacogenomics in order to initiate 
collaborative projects in this field to the 
benefit of society. Previous Golden Helix 
Pharmacogenomics Days have been organ­
ized in Athens (Greece; 7 May 2009), 
Thessaloniki (Greece; 15 April 2010) and 
Alexandroupolis (Greece; 8 April 2011).
The 4th Golden Helix Pharmaco­
genomics Day was organized in Cagliari 
(Italy) by the Golden Helix Institute of 
Biomedical Research and the Bernard B 
Brodie Department of Neurosciences of the 
University of Cagliari (Cagliari, Italy) and 
supported by the Foundation of the Bank 
of Sardinia and Beijing Genome Institute. 
The 5th Golden Helix Pharmacogenomics 
Day was organized in Msida (Malta) by 
the Golden Helix Institute of Biomedical 
Research and the Faculty of Medicine of 
the University of Malta and supported 
by the Foundation of Medical Sciences, 
Affymetrix, Illumina, QIAGEN, and the 
Mediterranean Bank. Both meetings were 
under the auspices of the European Society 
of Pharmacogenomics and Theranostics 
[102] and were attended by over 160 regis­
tered participants each. Here, we provide 
a report and present the highlights of these 
meetings.
4th Golden Helix 
Pharmacogenomics Day
Pharmacogenomics has an integral part 
in modern medical practice. George P 
Patrinos (University of Patras, Greece) out­
lined the key aspects of pharmacogenom­
ics, their implications in personalized med­
icine, and the most important applications 
in cancer, cardiovascular and psychiatric 
disorders, both in terms of drug efficacy 
and toxicity. Patrinos, also alluded to the 
importance of the incorporation of phar­
macogenomics in developing countries in 
Europe, not only to rationalize drug use but 
also to reduce the overall healthcare costs 
[2]. Next, Giovanni Severino (University of 
Cagliari) also stressed the importance of 
pharmacogenomics to predict adverse drug 
reactions so that the patient’s quality of life 
is improved. Successful implementation of 
pharmacogenomics strongly relies on regu­
latory agencies. Roberto De Lisa (EMA, 
London, UK) presented the regulatory 
activities related to pharmaco genomics and 
personalized medicine at the level of the 
EMA. The Pharmacogenomics Working 
Party (PgWP) provides recommendations 
to the Committee for Medicinal Products 
for Human Use (CHMP) on all matters 
relating directly or indirectly to pharma­
cogenomics. Some examples of product 
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information recently updated to include 
information on pharmacogenomics on 
the basis of pharmacovigilance data are 
 carbamazepine in relation to HLA‑A*1502. 
Federico Innocenti (University of 
North Carolina, NC, USA) discussed 
about the discovery of pharmacodynamic 
and pharmacokinetic biomarkers for drug 
response in cancer patients. Innocenti 
presented some recent work on the dis­
covery of genetic variants in genes of the 
VEGF (angiogenesis) pathway (pharmaco­
dynamics), and genetic variants involved 
in the regulation of gene expression in the 
human liver, the main organ of drug dispo­
sition (pharmacokinetics). In these studies, 
integrated approaches using  clinical and 
molecular data were performed [3]. 
In the current post­human genome 
project era, next­generation sequencing 
(NGS) technologies promise to acceler­
ate human genetic studies tremendously. 
Grover Yu (Beijing Genome Institute, 
China) presented the various NGS applica­
tions offered by BGI to identify important 
rare variants, understand disease inherit­
ance and realize the goal of therapies based 
on personal genomics. NGS technologies 
make these goals possible and promise 
a way to exploit the  complexity of the 
human genome. 
Hemoglobinopathies are the com­
monest single gene disorders in the 
Mediterranean basin. Renzo Galanello 
(University of Cagliari) presented recent 
data outlining the impact of pharmacog­
enomics in iron­overload treatment, while 
also stressing the importance of KLF1 
mutations in increasing fetal hemoglobin 
production in adults, which holds promise 
for novel therapeutic modalities for hemo­
globinopathies [4]. Giovanni Caocci (Bone 
Marrow Transplant Center, R Binaghi 
Hospital, Cagliari, Italy) described the 
application of tyrosine kinase inhibi­
tors to treat chronic myeloid leukemia 
(CML), in particular the use of imatinib 
and the second generation of tyrosine 
kinase inhibitors that are also available 
today (dasatinib and nilotinib). Overall 
survival of CML patients has increased up 
to 85–90% after 5 years of therapy, trans­
forming CML from a fatal leukemia in a 
chronic illness with a good quality of life.
Finally, Alessio Squassina (University 
of Cagliari) presented a wide overview of 
the pharmacogenomics of lithium response 
in bipolar disorder. Squassina presented 
evidence based on a genome­wide asso­
ciation study study on bipolar patients 
of Sardinian ancestry characterized for 
lithium response, suggesting that  ACCN1 
may play a key role in lithium treatment 
response [5]. 
As with every genomics approach, bio­
informatics and data management are of 
utmost importance. Patricia Rodriguez­
Tomè (CRS4, Pula, Cagliari, Italy) out­
lined the importance of bioinformatic 
tools in the analysis of large amounts of 
genomic data, and presented examples of 
their use, focusing on genomic databases. 
Similarly, Stefano Calza (University of 
Brescia, Italy) illustrated how data min­
ing and machine­learning algorithms can 
be applicable in the context of modern life 
sciences, in particular developing predic­
tive models, designing better clinical tri­
als and understanding how (candidate) 
genomic markers can be incorporated into 
study design for the development of new 
drugs. Finally, Valeria Deiana (University 
of Cagliari) presented a clinical database 
that has been developed to document 
detailed clinical and phenotypic informa­
tion of bipolar disease patients, such as the 
longitudinal course of illness, presence of 
psychotic symptoms and suicidal behavior, 
and psychiatric comorbidity. 
5th Golden Helix 
Pharmacogenomics Day
The importance of pharmacogenomics 
and personalized medicine was empha­
sized by European Commissioner for 
Health and Consumer Policy, John Dalli, 
who officially opened the event [103]. 
Christian Scerri (University of Malta) pre­
sented the opportunities that a small island 
like Malta can offer to pharmacogenom­
ics, strongly related to the participation of 
Malta to the Pharmacogenomics for Every 
Nation Initiative (PGENI) [104], which also 
endorsed this event. Pharmacogenomics 
should be successfully incorporated in 
the clinic to maximize their usefulness 
to the patients. Ron van Schaik (Erasmus 
University Medical Center, Rotterdam, 
The Netherlands) presented the experi­
ences of one of the biggest hospitals in 
The Netherlands in the integration of 
pharmaco genomics into mainstream 
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clinical practice and how pharmaco­
genomic information can be communi­
cated between various healthcare profes­
sionals across the country. 
Marisa Papaluca­Amati (EMA) deliv­
ered her presentation by live videoconfer­
encing and described the contribution and 
activities of a major regulatory agency to 
the development and applications of phar­
macogenomics [105]. Pharmacogenomics 
has fast entered the clinical arena, and 
the EMA emphasis now focuses on clini­
cal translation of pharmacogenomic data 
for personalized medicines, encouraging 
the incorporation of pharmacogenomic 
methods into clinical trials, and enter­
ing into dialogue with industry in order 
to explore the therapeutic benefits and 
risks within genetically defined patient 
subgroups. In addition, Jean­Luc Sanne 
(Directorate General for Health, European 
Commission, Belgium) outlined the cen­
tral role of personalized medicine into 
framework program 7 (FP7) for health.
There are currently very few clinical 
applications for pharmacogenomics on 
the market. Laura Uribe (Affymetrix Ltd, 
Singapore) discussed microarray technol­
ogy as a tool for genotyping pharmaco­
genomic markers and generating infor­
mation which is translatable to bedside 
applications. Uribe focused on the DMET+ 
array, which genotypes 1936 known phar­
macogenomic markers in 225 genes related 
to drug metabolism and transport, includ­
ing 99% of the absorption, distribution, 
metabolism and excretion core markers as 
defined by the PharmaAdme Group [106]. 
The DMET+ array is the basis for the 
ongoing PGENI project [104], which aims 
to produce a worldwide map for ethnic­
specific pharmacogenomic marker allele 
frequencies. 
The keynote lecture was delivered by 
Patrinos, who presented the impact of 
pharmacogenomics not only to modern 
medical practice but also to society. He 
also presented preliminary data from the 
ana lysis of healthy Maltese volunteers 
for the PGENI project, which indicate 
some very interesting deviations from 
certain pharmacogenomic marker allele 
frequencies compared with the Caucasian 
group, further supporting the impor­
tance of PGENI to rationalize drug use in 
 developing c ountries [2]. 
Andrew Webb (QIAGEN GmbH, 
Germany) gave an overview of the current 
trends in personalized healthcare and the 
roles of the pharmaceutical and diagnostic 
industries in the development of compan­
ion diagnostics to predict which patients 
are most likely to benefit from a particu­
lar therapy in advance. Webb highlighted 
that the use of companion diagnostics will 
provide a solution to stratify patients into 
therapeutic groups and eliminate the ‘trial 
and error’ approach. He also discussed the 
current companion diagnostic tests and 
the technologies used for implementation. 
In addition, Gustav Karlberg (Illumina 
Ltd, UK) gave an overview of the current 
tools and methods for Pharmacogenomics. 
Godfrey Grech (University of Malta) 
presented an overview of the molecular 
aspects of pharmacogenomics. He empha­
sized that the use of biomarkers to derive 
knowledge required for the classification 
of patients into therapeutic groups has 
been extensively used in various malig­
nancies [6,7]. Following on from Grech, 
Anthony Fenech (University of Malta) 
discussed molecular aspects of pharma­
cogenomics throughout the process, from 
drug development applications to bedside 
personalized medicine. Fenech finished 
by discussing the roles of microarrays 
and whole­genome sequencing in phar­
macogenomic ana lysis, and commented 
that further answers to interpatient drug­
response variability questions may not only 
be found in the genome.
Alessio Squassina (University of 
Cagliari) discussed pharmacogenetic 
testing of bipolar disorder and presented 
a comprehensive overview of all candi­
date genes known thus far to influence or 
predispose to bipolar disorder. Squassina 
presented data indicating that an impor­
tant variant in ACCN1 was associated 
with response to lithium treatment in 
Sardinian patients with bipolar disease 
[5]. He also stressed the ‘Consortium on 
Lithium Genetics’ (ConLiGen) initiative 
is also involved in the validation and iden­
tification of the key genes responsible for 
lithium therapy and personalized medi­
cine [107]. Finally, Joseph Borg (University 
of Malta) presented the impact of phar­
macogenomic testing on hemoglobin 
related disorders. Borg presented data sug­
gesting that genomic biomarkers can be 
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correlated to response to fetal hemoglobin 
augmenting therapies, while a novel gene 
can be related to increased fetal hemo­
globin in adults and as such can be tar­
geted for novel  therapeutic modalities for 
 thalassemia [8].  
Conclusion
The 4th and 5th Golden Helix Pharmaco­
genomics Days highlighted various areas of 
interest in pharmacogenomics, where many 
internationally renowned scientists gave 
excellent overviews of the existing applica­
tions and demonstrated the rapid pace and 
the direction in which the field is moving. 
The Golden Helix Institute of Biomedical 
Research aims to establish the Golden Helix 
Pharmacogenomics Days as one of the 
main educational and outreach activities 
for PGENI [104] in developing countries in 
Europe. Educational and training activities 
for healthcare professionals on pharmacog­
enomics will significantly contribute to the 
adoption of pharmacogenomics particularly 
in developing countries and, reciprocally, to 
the spread of pharmacogenomics applica­
tions to the benefit of the general public 
in these countries [1,2]. Finally, these events 
have also laid the foundations for the 6th and 
7th Golden Helix Pharmacogenomics Days 
scheduled for 5 June 2012 and 20 October 
2012 in Belgrade, Serbia, and Patras, Greece, 
respectively.
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